Atenolol gel used for treating infantile hemangioma, preparation method and applications

Abstract

The invention belongs to the technical field of medicines, and discloses atenolol gel used for treating infantile hemangioma, a preparation method and applications. The atenolol gel used for treating infantile hemangioma includes 5% of atenolol gel. The atenolol gel consists of atenolol and solid gel. The content of the atenolol in each gram of the atenolol gel is 50 mg. The preparation method of the atenolol gel includes obtaining the atenolol gel by mixing 50 mg of the atenolol and the solid gel. The atenolol gel can be used for treating infantile hemangioma, and is good in treatment effect, less in adverse reaction, wide in indication; and the atenolol gel is longer in half life, less in drug use frequency, better in medical compliance, and lower in cost. By using the atenolol gel to treat the hemangioma in an external use manner, risks of adverse reactions, such as gastrointestinal discomfort (diarrhea) and mood changes, caused by oral drugs can be avoided.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to an atenolol gel for treating infantile hemangioma, a preparation method and application. Background technique [0002] Currently: The current first-line treatment for infantile hemangioma is oral propranolol, because propranolol is a non-selective β-adrenoceptor blocker, acting on both β-1 and β-2 receptors , there is a potential risk of hypoglycemia and airway spasm. [0003] Atenolol is a selective β-1 adrenergic receptor blocker, it does not act on β-2 adrenal receptors, and there is no risk of hypoglycemia and airway spasm. Although existing studies have shown that atenolol can treat hemangiomas, the existing technology is achieved by oral atenolol, although oral atenolol can effectively treat infantile hemangiomas, and the risk of adverse reactions is relatively low. Propranolol is smaller, but oral medication still has the risk of adverse reactions such as ga...

AI Technical Summary

Problems solved by technology

Although existing studies have shown that atenolol can treat hemangiomas, the existing technology is achieved by oral atenolol, although oral atenolol can effectively treat infantile hemangiomas, and the risk of adverse reactions is relatively low. Propranolol is smaller, but oral medication still has the risk of adverse reactions such as gastrointestinal discomfort (diarrhea), mood changes, and at the same time, its use in children with congenital cardiovascular diseases is also limited

[0004] For superficial infantile hemangioma, timolol eye drops is currently the main drug for external use in the treatment of infantile hemangioma, but this preparation is easy to evaporate when used on the skin surface, the action time is short, and high-frequency application is required. And poor penetration for larger hemangiomas

[0005] Through the above analysis, the problems and defects in the prior art are: the existing drugs for the treatment of infantile hemangiomas have many adverse reactions, low safety, and high cost; The risk of adverse reactions such as gastrointestinal discomfort (diarrhea) and mood changes is also limited in children with congenital cardiovascular diseases; and the current external drugs have short action time and poor penetration strong, inconvenient to use

[0006] The difficulty in solving the above problems and defects is: the current first-line treatment for infantile hemangioma is oral propranolol, and propranolol is a non-selective β-receptor blocker with potential low The risk of blood sugar and airway spasm; studies have shown that atenolol, as a selective β-1 adrenergic receptor blocker, is used orally for the treatment of infantile hemangioma, and the therapeutic effect is not inferior to propranolol, but adverse Fewer reactions than propranolol

However, the corresponding method of oral timolol for the treatment of hemangiomas can lead to the risk of adverse reactions such as gastrointestinal discomfort (diarrhea), mood changes, etc. At the same time, its use in children with congenital cardiovascular diseases is also received However, for superficial infantile hemangioma, the existing topical drugs have short action time, weak penetration, and inconvenient use

Images